Plato Investment Management Ltd Has $1.27 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Plato Investment Management Ltd cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.0% in the first quarter, Holdings Channel.com reports. The institutional investor owned 4,659 shares of the biopharmaceutical company’s stock after selling 888 shares during the period. Plato Investment Management Ltd’s holdings in Alnylam Pharmaceuticals were worth $1,272,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in ALNY. Vanguard Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after acquiring an additional 323,206 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock valued at $1,192,988,000 after purchasing an additional 33,696 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Alnylam Pharmaceuticals by 5.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after purchasing an additional 185,783 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Alnylam Pharmaceuticals by 9.8% in the first quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company’s stock worth $475,353,000 after buying an additional 156,411 shares during the period. Finally, Orbis Allan Gray Ltd grew its holdings in shares of Alnylam Pharmaceuticals by 11.0% during the first quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company’s stock valued at $441,462,000 after buying an additional 162,121 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on ALNY. Canaccord Genuity Group raised their price objective on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Needham & Company LLC increased their price target on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Wolfe Research raised shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research report on Monday, August 4th. Piper Sandler increased their target price on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Finally, Oppenheimer raised shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 target price for the company in a research note on Monday, August 4th. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $417.38.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,455 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total transaction of $666,986.55. Following the transaction, the executive vice president owned 20,221 shares in the company, valued at $9,269,508.61. This trade represents a 6.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the transaction, the director directly owned 16,804 shares in the company, valued at approximately $7,561,800. This represents a 40.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,594 shares of company stock worth $25,551,456 in the last 90 days. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 2.7%

Alnylam Pharmaceuticals stock opened at $469.31 on Thursday. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $484.21. The firm’s fifty day simple moving average is $396.04 and its 200-day simple moving average is $313.80. The company has a market capitalization of $61.52 billion, a P/E ratio of -190.00 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same period in the prior year, the business posted ($0.13) earnings per share. The business’s quarterly revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.